Cell Treatments for Heart Infections – FDA Preclinical Point of view.


105 views
Uploaded on:
Category: Sports / Games
Description
Cell Treatments for Cardiovascular Maladies – FDA Preclinical Point of view Richard D. McFarland Ph.D., M.D. CBER/OCTGT/DCEPT BRMAC # 37 Walk 18-19, 2004 Extent of Talk Structure for FDA Audits Preclinical Models for Cardiovascular Infections Presentation of Exploratory Speakers
Transcripts
Slide 1

Cell Therapies for Cardiac Diseases – FDA Preclinical Perspective Richard D. McFarland Ph.D., M.D. CBER/OCTGT/DCEPT BRMAC # 37 March 18-19, 2004

Slide 2

Scope of Talk Framework for FDA Reviews Preclinical Models for Cardiac Diseases Introduction of Scientific Speakers

Slide 3

FDA Review is Product-based Parallels judicious item improvement Dependent on qualities of particular item Preclinical studies intended to bolster utilization of particular items Clinical trial configuration upheld by assembling, preclinical information Framed by regulations

Slide 4

Investigational New Drug (IND) Regulations 21 CFR312.23 (8) Adequate data about pharmacological and toxicological investigations of the medication including research center creatures or in vitro , on the premise of which the backer has inferred that it is sensibly protected to lead the proposed clinical examinations. The kind , length of time , and extent of creature and different tests obliged changes with the term and nature of the proposed clinical investigations…..

Slide 5

IND Regulations 21CFR312.23 (8)(ii)(b) For every toxicology think about that is expected principally to bolster the security of the proposed clinical examination, a full organization of information suitable for nitty gritty audit …..

Slide 6

Goals of Preclinical Evaluation Provide method of reasoning for proposed treatment Discern instrument of activity Identify “at risk” quiet populaces Recommend safe beginning dosages and acceleration plans for people Preliminary danger/advantage appraisal Identify parameters for clinical checking

Slide 7

Use of Preclinical Models of Cellular Therapies Scientific justification with the phone item planned for clinical utilization Understanding of cell capacity, trafficking and separation Modeling of courses of organization

Slide 8

Characteristics of Ideal Animal Model for Cardiac Cell Therapies Similar pathophysiology to people Improves consistency of human dangers Similar life structures to people Allows displaying of catheter utilization with clinical catheter Allows for measurement investigation Immune resilience to human cells Allows utilization of clinical cell item

Slide 9

Syngeneic Animal Models of Cardiac Diseases Can give valuable information to evaluation of wellbeing Analogous cell source from creatures Potential handling, definition, and capacity contrasts Limited item portrayal presents vulnerability

Slide 10

Complexity because of Innovative Delivery Systems Intraoperative transepicardial infusion (typically CABG) Catheter-intervened transendocardial infusion Catheter-interceded through heart vein

Slide 11

Small Animal Models in Published Literature Cryoinjury or coronary corridor ligation principally used to produce harmed myocardium Immunocompromised creatures accessible (mouse and rodent) Species utilized Mouse Rat Rabbit

Slide 12

Large Animal Models in Published Literature Ameroid constrictor essentially used to produce ischemic range Amenable to catheter organization Amenable to clinical observing modalities Species utilized Dog Sheep Pig

Slide 13

Potential Sources of Data to Support Initiation of Clinical Trials Preclinical concentrates particularly intended to bolster a clinical trial Other potential sources Existing creature studies intended to answer different inquiries In vitro contemplates Clinical trials utilizing the “same” item

Slide 14

Using Published Animal or Human Studies as Sole Support for Intiation of Clinical Trials Often they were not intended to answer a toxicologic inquiry, and accordingly, satisfactory toxicology endpoints might not have been fused into the configuration Published reports must give adequate data to autonomous survey

Slide 15

Use of Published Studies (cont’d) Protocols must be adequately nitty gritty Specifics of the course of organization Catheter specifics, for example, personality, stream rates and weights Location of infusion in connection to ischemic district Must contain points of interest of “routine” observing and explanatory arrangements

Slide 16

Use of Published Studies (cont’d) Data must be introduced in adequate subtle element In-procedure and parcel discharge information (assembling) Complete study reports for creature and clinical studies

Slide 17

Use of Published Studies (cont’d) Cellular items utilized as a part of distributed reports may not be practically identical to the expected clinical item Insufficient information to permit equivalence evaluation Editorial imperatives

Slide 18

Regulatory Challenges Does the accommodation contain “sufficient data to survey dangers to the subjects in the proposed trial?” Were sufficient preclinical studies performed? Were information submitted in adequate subtle element to direct an autonomous audit? On the off chance that adequate information are available, are the dangers to human subjects preposterous and noteworthy?

Slide 19

Afternoon Speakers Focus on cells Doris Taylor, University of Minnesota Silviu Itescu, Columbia University Focus on gadgets D. Scratch Jensen, FDA/CDRH Robert Leder

Recommended
View more...